INTRODUCTION AND AIMS:
MIC cells are donor-derived monocytes that gain immunosuppressive properties after incubation with the proliferation inhibitor mitomycin C. METHODS: PBMCs were harvested from living donors by leukapheresis and MIC cells were manufactured under GMP conditions. Kidney transplant recipients received either 1.5x10E6 MIC cells per kg body weight on day -2 (N¼3, group A), or 1.5x10E8 MIC cells per kg body weight on day -2 (N¼3, group B) or day -7 (N¼4, group C) before living donor kidney transplantation. Patients received immunosuppressive therapy with CyA, EC-MPS and CS. Primary outcome measure was the frequency of adverse events (AE) on day 30. RESULTS: A total of 70 AEs including 4 severe AEs occurred in treated patients that were unrelated to MIC cell infusion. No positive cross match results, de novo donor specific antibodies, or rejection episodes but 2 infectious complications were recorded. Median serum creatinine on day 30 was 1.4 mg/dL with no significant proteinuria. In vitro, MIC cells were capable of inducing tolerogenic dendritic cells with low expression of costimulatory molecules CD80, CD86 and a 30% increase of immunosuppressive molecule CD103. During the observation phase beyond day 30 after surgery, serum creatinine remained stable (median 1.48 mg/dL on day 180) with no significant proteinuria (median 10 g/mol creatinine on day 180) and no rejection episodes. The patients from group C who received low-dose CyA and low-dose EC-MPS during the observation phase had no or only minimal reactivity against irradiated donor lymphocytes in mixed lymphocyte culture while reactivity against 3rd party lymphocytes was preserved. CD19þ B cells increased to a median of 300/mL until day 30 but decreased to a median of 35/mL on day 180. CD19þCD24highCD38high transitional Bregs increased from a median of 2% on day 30 to a median of 20% of the total CD19þ B cell pool on day 180. There was a strong increase in the plasma IL-10/TNFalpha ratio from a median of 0.05 before cell therapy to a median of 0.11 on day 180. CONCLUSIONS: In summary, MIC cell therapy represents a promising option for individualized immunosuppression after living donor kidney Transplantation. /kg BW), in addition to standard immunosuppression regimen (Basiliximab induction, Tacrolimus, Mycophenolate Mofetil and Steroids), and were compared to 10 concomitant KTR and to our whole KTR cohort transplanted throughout the study recruiting period. All included KTR were aged between 18 and 75 years and underwent first successful KTx from a cadaveric organ donor. KTR were considered ineligible for enrollment if they had a past history of malignant disease, active uncontrolled infection, EBV-negative status, panel reactive antibodies > 50% or cardiovascular instability post KTx. MSC were not matched with kidney recipient or donor's HLA. Primary endpoint concerns safety issues of MSC infusion after KTx. Secondary endpoints were defined as the impact of MSC on graft outcomes and immunity, as well as the occurrence of anti-MSC donor HLA antibodies. Glomerular filtration rate (eGFR) was estimated using MDRD equation. Anti-HLA detection and identification were done by Luminex solid phase antibody detection technology. Lymphocyte phenotyping was performed using flow-cytometry. Regulatory T cells (Tregs) were defined as CD4
þ lymphocytes.
RESULTS:
No hemodynamic or immune-allergic side-effect was noted at the time of MSC injection. One patient had a non-ST-elevation myocardial infarction (NSTEMI) 3h after MSC infusion. All patients and grafts in MSC group survived during the 1-year follow-up. Still, at day 286 post KTx, one MSC-treated patient required temporary hemodialysis in a context of sepsis, type B aortic dissection and STEMI. Incidences of opportunistic infections and AR were comparable among groups. At D7, eGFR in MSC-treated KTR reached 48.6 ml/min, compared to 32.5 ml/min in matched KTR (p¼ 0.07) and 29.3 ml/min in the cohort (p¼ 0.01). No difference was observed among groups in 90-day eGFR slopes or eGFR levels at 1 year. MSC-treated KTR showed increased frequencies of Tregs at D30 in comparison to concomitant controls. Four patients developed antibodies against MSC or shared kidney-MSC HLA, with only 1 reaching mean fluorescence intensity >1500. CONCLUSIONS: No safety signals were reported following a single infusion of allogeneic MSC at the time of KTx, except one questionable cardiac event. MSC therapy is associated with increased Treg proportion among CD4 þ cells and improved early allograft function. Long-term effects, including potential immunization against MSC, remain to be studied.
INTRODUCTION AND AIMS:
Many studies have proved that the use of basiliximab as induction therapy reduces the risk of acute rejection episodes in renal transplant patients on cyclosporine-based maintenance immunotherapy. Tacrolimus has overwhelmingly replaced cyclosporine in the maintenance immunosuppressive protocols in many transplant centres. This was based on many studies that showed lower rejection rates in tacrolimus based immunotherapy compared to cyclosporine. The aim of our study and meta-analysis is to explore the effect of basiliximab induction therapy on rate of rejection, patient and graft survival in standard-risk renal transplant patients with tacrolimus based maintenance immunotherapy. Secondary aims included assessment of basiliximab effect on creatinine change, new onset diabetes post-transplant and risk of CMV infection. METHODS: We conducted a systematic review in PubMed, Medline, Embase and Cochrane databases to identify studies and research work that assessed effect of basiliximab on renal transplant outcomes. Inclusion criteria for our meta-analysis were all studies that compared basiliximab to placebo induction therapy in standard risk renal transplant recipients. Data collected were the name of the first author, journal title, year of publication, country where the study was conducted, number of patients in basiliximab arm and in placebo arm, number of patients who had biopsy-proven rejection and graft survival in each arm. Random effects model was used for the meta-analysis. RESULTS: Of the 470 abstracts found in different databases, 81 were repetitions. 389 abstracts were screened, of which 380 were excluded. Ten papers were fully explored. Three of them were excluded due to short follow-up period. Seven papers were included in the meta-analysis. Forest plot analysis for rate of rejection during the follow-up period, post-transplant showed no significant difference between both groups. There was evidence of heterogenicity between included studies (I-squared ¼70.9%, p¼0.002). Overall risk difference was -0.03(95%CI: -0.09,0.02). Random-effect metaanalysis for patient and graft survival was performed using forest plot analysis and showed no significant effect of basiliximab induction on patient or graft survival compared to placebo. Overall risk difference was -0.01 (95%CI: -0.04, 0.01) and 0.00(95%CI:-0.00,0.01), respectively. Three of the included studies showed no effect of basiliximab on creatinine change .Two showed no effect on risk of CMV infection and one showed less risk of post-transplant diabetes in basiliximab group. CONCLUSIONS: Basiliximab induction therapy has no significant effect on rate of rejection patient or graft survival in standard-risk renal transplant recipients with V C The Author 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 
